- Senate passes Drug Quality and Security Act
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- PhRMA report lists 271 vaccines in development
- FDA advisory committees vote against changing naproxen label to highlight a lower CVD profile
- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
PITTSBURGH — The Food and Drug Administration has approved a treatment for shingles made by a subsidiary of generic drug maker Mylan.
Mylan announced Monday the approval of Matrix Labs’ gabapentin capsules in the 100-mg, 300-mg and 400-mg strengths. The drug is used to treat postherpetic neuralgia, a painful complication of shingles.
Gabapentin capsules had sales of about $300 million in 2010, according to IMS Health.